Wan-Nien Yu1, Heng-Fu Lin1, Y I Lee2, Wei-Chung Shia3, Wen-Wei Sung2,4,5, Chung-Min Yeh6,7, Yueh-Min Lin8,6. 1. Department of Otorhinolaryngology, Head and Neck Surgery, Changhua Christian Hospital, Changhua, Taiwan, R.O.C. 2. School of Medicine, Chung Shan Medical University, Taichung, Taiwan, R.O.C. 3. Cancer Research Center, Department of Research, Changhua Christian Hospital, Changhua, Taiwan, R.O.C. 4. Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, R.O.C. 5. Department of Urology, Chung Shan Medical University Hospital, Taichung, Taiwan, R.O.C. 6. Department of Surgical Pathology, Changhua Christian Hospital, Changhua, Taiwan, R.O.C. 7. Department of Medical Technology, Jen-Teh Junior College of Medicine, Nursing and Management, Miaoli, Taiwan, R.O.C. 8. School of Medicine, Chung Shan Medical University, Taichung, Taiwan, R.O.C.; 93668@cch.org.tw.
Abstract
BACKGROUND/AIM: To investigate the impact of PDZ-binding kinase (PBK) on the clinical outcome of patients with oral squamous cell carcinoma (OSCC) who received radiotherapy. PATIENTS AND METHODS: PBK immunoreactivity of cancer specimens obtained from 179 patients with primary OSCC was analyzed by immunohistochemistry. RESULTS: High PBK expression in tumor cells tended to be associated with advanced N-stage. The 5-year survival rate was greater for patients with high total PBK expression than in those with low PBK expression. After adjustment, high PBK remained associated with a favorable outcome. In subgroups according to tumor stage, the prognostic role was significant in patients with stage III/IV rather than those with stage I/II disease. CONCLUSION: We suggest that PBK expression should be used as an independent prognostic marker for patients with OSCC treated with radiotherapy, especially for those with advanced-stage disease.
BACKGROUND/AIM: To investigate the impact of PDZ-binding kinase (PBK) on the clinical outcome of patients with oral squamous cell carcinoma (OSCC) who received radiotherapy. PATIENTS AND METHODS: PBK immunoreactivity of cancer specimens obtained from 179 patients with primary OSCC was analyzed by immunohistochemistry. RESULTS: High PBK expression in tumor cells tended to be associated with advanced N-stage. The 5-year survival rate was greater for patients with high total PBK expression than in those with low PBK expression. After adjustment, high PBK remained associated with a favorable outcome. In subgroups according to tumor stage, the prognostic role was significant in patients with stage III/IV rather than those with stage I/II disease. CONCLUSION: We suggest that PBK expression should be used as an independent prognostic marker for patients with OSCC treated with radiotherapy, especially for those with advanced-stage disease.